Filippo D. Marinis
Milan, 20141, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List.
Journal: Cancers
Published: April 30, 2025
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.
Journal: Future oncology (London, England)
Published: October 03, 2024
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Journal: Future oncology (London, England)
Published: June 12, 2023
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Journal: Future oncology (London, England)
Published: March 06, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Journal: Future oncology (London, England)
Published: January 19, 2023
Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study.
Journal: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
Published: November 30, 2020
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Journal: Future oncology (London, England)
Published: July 25, 2019
The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.
Journal: Immunotherapy
Published: September 07, 2018
Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.
Journal: Seminars in thoracic and cardiovascular surgery
Published: February 03, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026